Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...
March 24, 2010 — One year of maintenance risperidone administered at the initial therapeutic dose for acute schizophrenia is more effective at preventing relapse than dose reduction strategies and is ...
A major U.K. study of more than 165,000 dementia patients has found that risperidone raises stroke risk without exception, challenging safety assumptions by leaving no "safe group." Subscribe to our ...
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell ...
Health and Me on MSN
This widely used dementia drug may raise stroke risk in all patients, study finds
A large UK study of over 165,000 dementia patients finds risperidone raises stroke risk in all users, prompting concerns over prescribing, monitoring, and dementia care guidelines. Keep reading for ...
Patients. A total of 675 patients were involved in the ITT analysis (risperidone group, n = 349; conventional antipsychotic group, n = 326). The baseline demographics and the clinical characteristics ...
About UZEDY UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for the treatment of schizophrenia in adults. In clinical trials, UZEDY significantly reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results